Risk-stratified outcomes of nonmyeloablative HLA-haploidentical BMT with high-dose posttransplantation cyclophosphamideShannon R. McCurdy, Yvette L. Kasamon, Douglas E. Gladstone et al.|Blood|2015Cited by 299
Comparable composite endpoints after HLA-matched and HLA-haploidentical transplantation with post-transplantation cyclophosphamideShannon R. McCurdy, Leo Luznik, Yvette L. Kasamon et al.|Haematologica|2016Cited by 187
Chronic Myeloid Leukemia, Version 2.2024, NCCN Clinical Practice Guidelines in OncologyNeil P. Shah, Kristina M. Gregory, Ravi Bhatia et al.|Journal of the National Comprehensive Cancer Network|2024Cited by 116
Myeloablative haploidentical BMT with posttransplant cyclophosphamide for hematologic malignancies in children and adultsHeather J. Symons, Ephraim J. Fuchs, Marianna Zahurak et al.|Blood Advances|2020Cited by 73
CML and the WHO: Why?Ellin Berman, Brian Druker, Neil P. Shah et al.|Journal of Clinical Oncology|2023Cited by 14